DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20195677

Evaluation of newer imidazoles in dermatophytosis

Annie Ratnam Nakka, Janardhan Bommakanti, Siva Rami R. Karumuri, Naresh B. Thambisetti

Abstract


Background: Eberconazole, a newer Imidazole derivative, antimycotic drug. Similarly, sertaconazole and luliconazole are also newer antifungal which all exhibit fungicidal, fungistatic and anti-inflammatory actions. But, sertaconazole in addition have antipruritic effect also.

Methods: Randomized, open-labelled, prospective study comprising of 75 patients divided into three equal groups A, B, C of 25 patients each. Group A received eberconazole 1%, Group B received sertaconazole 2% and Group C received luliconazole 1% for twice daily topical application for 4 weeks. Patients were asked to review at 2nd and 4th week to record clinical and mycological cure.

Results: In this study out of 75, seventy patients completed the complete course of treatment whereas, five patients were not reported for review citing personal reasons. Parameters included are pruritus, erythema, scaling and vesicles in all three groups. In this study, marked relief of pruritus was achieved clinically with eberconazole (72.7%) followed by luliconazole and sertaconazole with 50.0% and 33.3% respectively at 4th week of treatment phase and reduction of scaling was achieved more with eberconazole (90.9%), sertaconazole (87.5%) and luliconazole (83.3%). All three groups of patients showed successful mycological cure by confirming with negative 10% potassium hydroxide examination at the end of treatment course.

Conclusions: Eberconazole 1% cream was better than sertaconazole 2% cream and luliconazole 1% cream in relieving symptoms like pruritus and scaling at the end of treatment phase and follow up.


Keywords


Dermatophytosis, Tinea corporis, Tinea cruris, Eberconazole, Sertaconazole, Luliconazole

Full Text:

PDF

References


Mohanty JC, Mohanty SK, Sahoo RC, Sahoo AS, Praharaj CH. Incidence of dermatophytosis in Orissa. India J Med Microbiol 1998;16:78-80.

Singh S, Beena MP. Profile of dermatophyte infections in Baroda. Indian J Dermatol Venereol Leprol. 2003;69:281-3.

Moodahadu-bangera LS, Martis J, Mittal R, Krishnankutty B, Kumar N, Bellary S, et al. Eberconazole-pharmacological and clinical review. IJDVL. 2012;78:217-22.

Jerajani HR, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertoconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: a pilot study. IJD. 2013;58:34-8.

Bindu V, Pavithran K. Clinico-mycological study of dermatophytosis in Calicut. Indian J Dermatol Venereol Leprol. 2002;68:259–61.

Smita Sarma, AK Borthakur. A clinico-epidemiological study of dermatophytoses in northeast India. Indian J Dermatol Venereal Leprol. 2007;73:427-8.

Chandana T, Saritha C, Shankariah P. Comparison of safety and efficacy of luliconazole and other antifungal agents. IJPSR. 2014;5.

Montero TR, Lopez S, Roriguez C, Rio R, Badell A, Gratacos MR. Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment : multicenter, randomized, double-blind, comparative trial with miconazole 2% cream. Int J Dermatol. 2006;45:600-4.

Choudary SV, Aghi T, Bisati S. Efficacy and safety of terbinafine hydrochloride 1% cream vs eberconazole nitrate 1% cream in localized Tinea corporis and Tinea cruris. IDOJ. 2014;5:128-31.

Barbanoj MJ, Antonijoan R, García-Gea C, Puntes M, Gich I, Jané F, et al. Eberconazole cream: topical and general tolerability, sensitisation potential, and systemic availability. Methods Find Exp Clin Pharmacol. 2005;27:227-34.

Sharma J, Kaushal J, Aggarwal K. A comparative study of efficacy and safety of eberconazole versus terbinafine in patients of Tinea versicolor. IJD. 2018;63:53-6.